[Impase in the treatment of erectile dysfunction].
The authors review epidemiology, classification, etiology and pathogenesis of erectile dysfunction (ED), its diagnosis and treatment with a focus on mechanisms of action and efficacy of the drug impase. Impase is the drug of superlow doses of affinitively purified potentiated antibodies to human endothelial NO-synthase. The drug regulates NO synthesis in the cavernous bodies, enhances an NO relaxing action on their smooth muscles and blood flow in the penis under sexual stimulation. The drug demonstrated its high efficacy and safety in many clinical trials. Impase trial performed in the Research Institute of Urology in 2004 has found that impase is more effective in long-term administration, most of the examinees exhibited a clinical response only after one month of regular intake. The drug can be used both as the first-line monotherapy of ED and combined treatment of this disease. Clinical recommendations for practitioners on administration of impase are provided.
Kamalov
A A
AA
Dorofeev
S D
SD
Efremov
E A
EA
D000328:Adult; D000906:Antibodies / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D019001:Nitric Oxide Synthase / Q000276:immunology*
D000906:Antibodies; D019001:Nitric Oxide Synthase